Single therapy offers improved survival in younger patients with limited brain metastases
the ONA take:
A study that analyzed patient data from the three largest randomized clinical trials of stereotactic radiosurgery (SRS) and whole brain radiation therapy (WBRT) found that in patients with cancer who are ages 50 years and younger should receive SRS without WBRT.
The meta-analysis examined data from a total of 364 patients from an Asian trial (JROSG99-1), published in 2006; a North American trial (MDACC NCT00548756), published in 2009; and a European trial (EORTC 22952-26001), published in 2011.
The data showed that SRS alone yielded improved overall survival (OS) in patients ages 50 years and younger. Median survival for these patients was 13.6 months after treatment with SRS alone, whereas patients in the same age group who received SRS plus WBRT had a median survival of 8.2 months.
Patients older than 50 years who underwent SRS along had a median survival of 10.1 months, and 8.6 months for those who received SRS plus WBRT.
The researchers reported expecting to see improved survival in patients who received therapy combining SRS and WBRT.
However, these data clearly demonstrated SRS alone offered benefits for younger patients with limited metastases.
Data clearly demonstrated stereotactic radiosurgery alone offered benefits for younger patients with limited metastases.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|